The 2021 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2021. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is Thursday, November 19, 2020 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is Monday, January 11, 2021 (11:59 p.m. ET).

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, a new submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.
Tumor microcirculation and the Novel pro- and antiangiogenic factors
Molecular mechanisms of angiogenesis
Host-tumor interactions
Angiogenesis and angiogenesis inhibitors
Host-tumor interactions
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Tumor microcirculation and the microenvironment
Other

Tumor Biology

Nonclinical Models of Cancer
3-D and tissue recombinant models
Developmental phenotypes of cancer genes
Human-in-mouse models of human cancer
Model organisms in drug discovery
Mouse models of human cancer
Noninvasive imaging in animal models
Organooids
Patient-derived xenograft models
Zebrafish models of cancer
Other animal and cell models of cancer
Other

Stem Cell Biology

Adult stem cells
Cancer stem cells
Developmental pathways in cancer
Embryonic stem cells
Stem cell markers
Stem cells and regenerative medicine in oncology
Other

Tumor Adhesion

Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
Other

Invasion and Metastasis

Actin cytoskeleton
Biomarkers of metastasis
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Genes that regulate migration and invasion
Imaging of tumor progression and metastasis
Invasion and migration
Metastasis suppressor genes
Metastasis-promoting genes
Premetastatic niche
Therapeutic metastasis prevention
Other

Angiogenesis

Angiogenesis and angiogenesis inhibitors
Host-tumor interactions
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Tumor microcirculation and the microenvironment
Other

Tumor Microenvironment

Chemokines in the microenvironment
Drug targets in the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Immunity and the microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other

In Vivo Imaging

Advanced nanotechnology and imaging
Application of imaging technology to the clinic
Imaging in animal models
Imaging of molecular and cellular events in the tumor microenvironment
Imaging of molecular and cellular events in tumors and tumor cells
Imaging the immune response
Imaging tumor metabolism
New targets for imaging
Other

Pediatric Cancer - Basic Science

Developmental origins and drivers of pediatric cancer
Pediatric cancer epigenomics and genomics
Pediatric cancer models
Pediatric cancer tumor microenvironment and tumor heterogeneity
Other

Radiation Science

Modulators of radiation response
Photobiology/photodynamic therapy
Radiation dose fractionation
Radiation-activated signaling pathways
Radiation-induced gene expression
Radiation-induced resistance
Radiobiology research
Radioprotectors and radiosensitizers
Other

Carcinogenesis

Carcinogenesis: Chemical, environmental, and molecular
Mutagenesis
Tumor initiation and promotion
Viral-induced carcinogenesis
Other

In Vivo Imaging

Advanced nanotechnology and imaging
Application of imaging technology to the clinic
Imaging in animal models
Imaging of molecular and cellular events in the tumor microenvironment
Imaging of molecular and cellular events in tumors and tumor cells
Imaging the immune response
Imaging tumor metabolism
New targets for imaging
Other

Drug Discovery, Design, and Delivery

Basic and applied nanotechnology and therapeutics
Cheminformatics, in silico screening, and computational methods
Drug delivery
Drug design
High-throughput screening (assays and libraries)
Lead identification
Lead optimization
Nanotechnology drug delivery
Natural products
Synthesis, metabolism, and disposition
Other

Structural and Chemical Biology

Chemical genetics and genomics
Nanotechnology in chemical biology
Small molecule, protein, and nucleic acid interactions
Target identification, small molecule probes, and libraries
X-ray and NMR structures
Other

Proteomics and Mass Spectrometry

Biological mass spectrometry and systems biology
Proteomics and biomarker discovery
Proteomics and signaling networks
Other
<table>
<thead>
<tr>
<th>ET</th>
<th>Experimental and Molecular Therapeutics</th>
</tr>
</thead>
</table>
| **ET01** Drug Discovery | Antibody technologies  
Biochemical modulators of the therapeutic index  
Combination chemotherapies  
Differentiation therapy  
New targets  
Novel assay technology  
Novel drug delivery systems  
Targeting the tumor microenvironment in drug development  
Other |
| **ET02** Mechanisms of Drug Action | Cell cycle mechanisms of anticancer drug action  
Cellular responses to anticancer drugs  
Interactions of new agents with radiation  
Role of the microenvironment in therapeutic response  
Other |
| **ET03** Drug Resistance | Drug resistance in molecular targeted therapies  
Drug transport and metabolism  
Novel mechanisms  
Regulation of gene expression in drug resistance  
Reversal of drug resistance  
Other |
| **ET04** Molecular Targets | Cell death pathways and treatment  
Identification of molecular targets  
Modulation of DNA repair  
Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes  
New nonclinical models for targets  
Other |
| **ET05** Pharmacology, Pharmacogenetics, and Pharmacogenomics | Cellular pharmacology  
Molecular pharmacology  
Pharmacogenetics and therapeutic response  
Pharmacogenomics  
Pharmacokinetics and pharmacodynamics  
Preclinical toxicology  
Other |
| **ET06** Small Molecule Therapeutic Agents | DNA-reactive agents  
Epigenetic targets  
HDAC and methyltransferase inhibitors  
Novel antitumor agents  
Novel targets and pathways  
PIM1/AKT inhibitors  
Proteasome inhibitors  
Topoisomerases  
Tubulin agents  
Tyrosine kinase and phosphatase inhibitors  
Other |
| **ET07** Biological Therapeutic Agents | Antireceptors  
Apoptosis: Therapeutic manipulation  
Growth factor receptors and other surface antigens as targets for therapy  
Oncogenes, tumor suppressor genes, and gene products as targets for therapy  
Protein kinases and phosphatases as targets for therapy  
Role of microenvironment in therapeutic response  
Other |
| **ET08** Gene and Vector-Based Therapy | Antisense molecules  
Gene therapy and radiation studies  
Immune modulators  
Vector systems and targeting strategies  
Other |
| **ET09** Preclinical Radiotherapeutics | Modification of radiosensitivity  
Molecular targets of radiation response  
Normal tissue/cellular stress responses to radiation  
Radioprotectors and radiosensitizers  
Radiotherapeutic combinations  
Other |

<table>
<thead>
<tr>
<th>IM</th>
<th>Immunology</th>
</tr>
</thead>
</table>
| **IM01** Tumor Immunobiology | Adaptive immunity in tumors  
Epigenetic regulation of tumor immunity  
Inflammation and cancer: Metastasis  
Inflammation and cancer: Tumor initiation and progression  
Innate immunity to tumors  
Microbiome, inflammation, and cancer  
Novel animal models  
Oncogenic pathway-mediated regulation of inflammation and tumor immunity  
Tumor antigenicity/processing and presentation  
Tumor-induced immune suppression: Extrinsic factors  
Tumor-induced immune suppression: Intrinsic factors  
Other |
| **IM02** Immunotherapy, Preclinical and Clinical | Adoptive cell therapy  
Combination immunotherapies  
Immune checkpoints  
Immune mechanisms invoked by other therapies including chemotherapy  
Immune mechanisms invoked by radiation therapy  
Immune monitoring/clinical correlates  
Immune response to therapies  
Immunomodulatory agents and interventions  
Inflammation, immunity, and cancer  
Modifiers of the tumor microenvironment  
Therapeutic antibodies, including engineered antibodies  
Vaccines (oncolytic and prophylactic)  
Other |

<table>
<thead>
<tr>
<th>CT</th>
<th>Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CT01</strong> Phase I Adult Clinical Trials</td>
<td>All clinical trials should be submitted by the January 11, 2021 clinical trials abstract deadline.</td>
</tr>
<tr>
<td><strong>CT02</strong> Phase II Adult Clinical Trials</td>
<td></td>
</tr>
<tr>
<td><strong>CT03</strong> Phase III Adult Clinical Trials</td>
<td></td>
</tr>
<tr>
<td><strong>CT04</strong> Phase I, II, or III Clinical Trials in Pediatric Cancer</td>
<td>(See also CL02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)</td>
</tr>
<tr>
<td><strong>CT05</strong> Phase I, II, or III Clinical Trials in the Elderly</td>
<td></td>
</tr>
<tr>
<td><strong>CT06</strong> Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations</td>
<td></td>
</tr>
<tr>
<td>ABSTRACT CATEGORIES</td>
<td>(cont’d)</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>CL07</strong> Clinical Trials for COVID-19</td>
<td>(See also COVID06: Clinical Trials (Phase I–Phase IV and Trials in Progress))</td>
</tr>
<tr>
<td>Phase I</td>
<td></td>
</tr>
<tr>
<td>Phase II</td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td></td>
</tr>
<tr>
<td>Phase IV, observational, and expanded access</td>
<td>Clinical trials in progress</td>
</tr>
<tr>
<td><strong>CT08</strong> Clinical Trials in Progress</td>
<td></td>
</tr>
<tr>
<td>Phase I clinical trials in progress</td>
<td></td>
</tr>
<tr>
<td>Phase II clinical trials in progress</td>
<td></td>
</tr>
<tr>
<td>Phase III clinical trials in progress</td>
<td></td>
</tr>
<tr>
<td><strong>CL01</strong> Clinical Research</td>
<td>(not including clinical trials; see also the Clinical Trials (CT) categories)</td>
</tr>
<tr>
<td><strong>CL02</strong> Pediatric Cancer – Clinical Investigations</td>
<td>(See also CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB08: Pediatric Cancer – Basic Science)</td>
</tr>
<tr>
<td>Adolescent and young adult oncology</td>
<td></td>
</tr>
<tr>
<td>Childhood cancer drug development</td>
<td></td>
</tr>
<tr>
<td>Immunotherapeutic approaches to pediatric cancer</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer predisposition and surveillance</td>
<td></td>
</tr>
<tr>
<td>Survivorship, late effects, and secondary cancers</td>
<td></td>
</tr>
<tr>
<td>Therapeutic dosing, resistance, and combination therapy approaches in pediatric oncology</td>
<td></td>
</tr>
<tr>
<td>Translational pediatric cancer research</td>
<td></td>
</tr>
<tr>
<td><strong>CL03</strong> Clinical Research in the Elderly</td>
<td>Aging, immunity, and cancer</td>
</tr>
<tr>
<td><strong>CL04</strong> Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations</td>
<td></td>
</tr>
<tr>
<td>Biobanking/biospecimen collection</td>
<td></td>
</tr>
<tr>
<td>Clinical trial design</td>
<td></td>
</tr>
<tr>
<td>Community engaged research/community-based participatory research</td>
<td></td>
</tr>
<tr>
<td>Patient accrual and retention</td>
<td></td>
</tr>
<tr>
<td>Patient navigation</td>
<td></td>
</tr>
<tr>
<td><strong>CL05</strong> Biostatistics in Clinical Trials</td>
<td>Design and analysis of clinical trials</td>
</tr>
<tr>
<td>New study designs: Theory, methodology, and modeling</td>
<td></td>
</tr>
<tr>
<td>Statistical modeling for cancer studies</td>
<td></td>
</tr>
<tr>
<td><strong>CL06</strong> Immuno-oncology</td>
<td>(See also ET07: Biological Therapeutic Agents; IM02: Immunotherapy, Preclinical and Clinical)</td>
</tr>
<tr>
<td>Adoptive cell therapy</td>
<td></td>
</tr>
<tr>
<td>Combination immunotherapies</td>
<td></td>
</tr>
<tr>
<td>Immune checkpoints</td>
<td></td>
</tr>
<tr>
<td>Immune mechanisms invoked by other therapies including chemotherapy</td>
<td></td>
</tr>
<tr>
<td>Immune mechanisms invoked by radiation therapy</td>
<td></td>
</tr>
<tr>
<td>Immune monitoring клинические корреляты</td>
<td></td>
</tr>
<tr>
<td>Immune response to therapies</td>
<td></td>
</tr>
<tr>
<td>Immunomodulatory agents and interventions</td>
<td></td>
</tr>
<tr>
<td>Inflammation, immunity, and cancer</td>
<td></td>
</tr>
<tr>
<td>Modifiers of the tumor microenvironment</td>
<td></td>
</tr>
<tr>
<td>Therapeutic antibodies, including engineered antibodies</td>
<td></td>
</tr>
<tr>
<td>Vaccines (oncolytic and prophylactic)</td>
<td></td>
</tr>
<tr>
<td><strong>CL07</strong> Radiation Oncology</td>
<td>(See also TB09: Radiation Science; ET09: Preclinical Radiotherapeutics)</td>
</tr>
<tr>
<td>Clinical radiotherapeutic studies</td>
<td></td>
</tr>
<tr>
<td>Interventional radiology</td>
<td></td>
</tr>
<tr>
<td>Modification of radiosensitivity</td>
<td></td>
</tr>
<tr>
<td>Radiation-immunotherapy and other radiotherapeutic combinations</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced late effects/secondary cancers</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced resistance</td>
<td></td>
</tr>
<tr>
<td><strong>CL08</strong> Surgical Oncology (including Prophylactic Surgery)</td>
<td>Surgical oncology</td>
</tr>
<tr>
<td><strong>CL09</strong> Clinical Endocrinology</td>
<td>(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)</td>
</tr>
<tr>
<td>Endocrine-related cancers</td>
<td></td>
</tr>
<tr>
<td>Hormone receptors and diagnosis/prognosis</td>
<td></td>
</tr>
<tr>
<td>Hormone signaling and inhibitors</td>
<td></td>
</tr>
<tr>
<td>Hormone synthesis, metabolism, and inhibitors</td>
<td></td>
</tr>
<tr>
<td>Neuroendocrine and other endocrine factors</td>
<td></td>
</tr>
<tr>
<td>Nuclear receptors: Structure and function</td>
<td></td>
</tr>
<tr>
<td>Preclinical studies of endocrine-related cancers</td>
<td></td>
</tr>
<tr>
<td>Receptors and signal transduction</td>
<td></td>
</tr>
<tr>
<td>Steroid hormone receptors</td>
<td></td>
</tr>
<tr>
<td><strong>CL10</strong> Survivorship Research and Supportive Care</td>
<td>Biological cell and tissue damage</td>
</tr>
<tr>
<td>Comparative effectiveness research and cost-effective studies</td>
<td></td>
</tr>
<tr>
<td>Late effects and second cancers</td>
<td></td>
</tr>
<tr>
<td>Psycho-oncology</td>
<td></td>
</tr>
<tr>
<td>Supportive care, palliation, and pain management</td>
<td></td>
</tr>
<tr>
<td>Translational survivorship research</td>
<td></td>
</tr>
<tr>
<td><strong>CL11</strong> Biomarkers</td>
<td>Biomarkers predictive of therapeutic benefit</td>
</tr>
<tr>
<td>Diagnostic biomarkers</td>
<td></td>
</tr>
<tr>
<td>Early detection biomarkers</td>
<td></td>
</tr>
<tr>
<td>Liquid biopsies: Circulating DNA</td>
<td></td>
</tr>
<tr>
<td>Liquid biopsies: Circulating tumor cells</td>
<td></td>
</tr>
<tr>
<td>Metastasis biomarkers</td>
<td></td>
</tr>
<tr>
<td>Prognostic biomarkers</td>
<td></td>
</tr>
<tr>
<td><strong>CL12</strong> Clinical Outcomes Research</td>
<td>Clinical outcomes research</td>
</tr>
<tr>
<td><strong>EN</strong> Endocrinology</td>
<td></td>
</tr>
<tr>
<td><strong>EN01</strong> Molecular, Preclinical, and Clinical Endocrinology</td>
<td>(See also CL09: Clinical Endocrinology)</td>
</tr>
<tr>
<td>Endocrine-related cancers</td>
<td></td>
</tr>
<tr>
<td>Growth factors, receptors, and signal transduction</td>
<td></td>
</tr>
<tr>
<td>Hormone receptors and diagnosis/prognosis</td>
<td></td>
</tr>
<tr>
<td>Hormone signaling and inhibitors</td>
<td></td>
</tr>
<tr>
<td>Hormone synthesis, metabolism, and inhibitors</td>
<td></td>
</tr>
<tr>
<td>Neuroendocrine and other endocrine factors</td>
<td></td>
</tr>
<tr>
<td>Nuclear receptors: Structure and function</td>
<td></td>
</tr>
<tr>
<td>Preclinical studies of endocrine-related cancers</td>
<td></td>
</tr>
<tr>
<td>Receptors and signal transduction</td>
<td></td>
</tr>
<tr>
<td>Steroid hormone receptors</td>
<td></td>
</tr>
</tbody>
</table>
EP Epidemiology (including Genetic, Molecular, and Integrative Epidemiology)

EP01 Epidemiology
- Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
- Biomarkers of prognosis
- Cancer health disparities research
- Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
- Diet, alcohol, tobacco use, and other lifestyle risk factors
- Environmental and occupational risk factors
- Familial and hereditary cancers
- Functional studies of genetic variants
- Gene-gene and gene-environment interactions
- Genome-wide association studies (GWAS)/post-GWAS
- Health services and comparative effectiveness research
- Infection and immune factors
- Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
- Pathway and candidate gene studies of risk or prognosis
- Pharmacoprevention
- Preneoplastic and tumor markers
- Primary and secondary intervention studies
- Risk prediction models for incidence, prognosis, and/or mortality
- Screening and early detection
- Statistical and epidemiological methodology
- Survivorship research
- Other

PR Prevention, Early Detection, and Interception

PR01 Preclinical Prevention, Early Detection, and Interception
- Animal models in prevention
- Biological and biochemical mechanisms in prevention
- Biomarkers and intervention studies
- Cellular models
- Chemoprevention studies
- Diet, nutrition, and cancer
- Microbiome and prevention
- Molecular markers in prevention research
- Molecular targets for prevention
- New agent development
- Screening and early detection
- Other

PR02 Clinical Prevention, Early Detection, and Interception
- Application of molecular pathology in clinical prevention
- Biomarkers and intervention studies
- Cancer health disparities research
- Cancer surveillance and screening studies
- Chemoprevention clinical trials
- Genetic markers as surrogate endpoints in prevention trials
- Genomics and proteomics in cancer risk and response assessment
- Infections and viral-related cancers
- Microbiome and prevention
- Prevention and treatment of premalignant lesions (intraperithelial neoplasia)
- Prevention of second cancers
- Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
- Screening and early detection
- Other

COVID COVID-19 and Cancer

COVID01 Intersection of the Biology of SARS-CoV-2 and Cancer
- Biomarkers/predictors of COVID-19 and cancer
- Host genomics and genetics
- Immunobiology
- Pathophysiology
- Viral evolution
- Other

COVID02 Diagnostics for COVID-19 Testing: Design, Development, and Validation

COVID03 Cancer Drug Repurposing to Treat COVID-19

COVID04 COVID-19 Vaccine Development

COVID05 Effects of Cancer Immunotherapies on Patients with COVID-19 (with or without Cancer)

COVID06 Clinical Trials
- (See also CT07: Clinical Trials for COVID-19 (Phase I-Phase IV and Trials in Progress))
- Phase I
- Phase II
- Phase III
- Phase IV, observational, and expanded access
- Clinical trials in progress

COVID07 Continuity of Cancer Care
- Long-term cancer outcomes
- Novel health care strategies (including telehealth and digital health)

Other

COVID08 Effects of COVID-19 on Cancer Survivorship
- Long-term health-related quality of life issues
- Psychosocial impact on patients and health care workers

COVID09 Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19

COVID10 Cancer Prevention and Early Detection during the COVID-19 Pandemic

COVID11 Epidemiology and Registries of COVID-19 and Cancer (including Biorepositories)

COVID12 Health Inequities and Disparities during the COVID-19 Pandemic

COVID13 Science and Public Policy
- Effects of regional public health policies
- Funding
- Regulatory science and policy
- Workforce
- Other

RSP Regulatory Science and Policy

RSP01 Regulatory Science and Policy
- Biosimilars and generics
- Clinical trial design and accrual
- Combination therapies and codevelopment of investigational agents and diagnostics
- Data science and informatics
- Novel endpoints and biomarkers
- Real-world evidence and retrospective analyses
- Tobacco and e-cigarette regulation
- Other

SHP Science and Health Policy

SHP01 Science and Health Policy
- Cancer health disparities
- Cancer survivorship
- Comparative effectiveness research
- Implementation science
- Patient advocacy and engagement
- Value and cost issues in cancer care
- Other